• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Kolltan Pharmaceuticals

edit

Kolltan Pharmaceuticals, Inc. develops new generation monoclonal antibody oncology therapeutics. Its products are developed based in receptor tyrosine kinase. The company was founded in 2007 and is based in New Haven, Connecticut.

Milestones

edit

• 
  Kolltan Pharmaceuticals added Gerald McMahon as President and CEO.
  Posted 4/23/12 at 6:32pm
• 
  Kolltan Pharmaceuticals added Thomas Neff as Director.
  Posted 1/4/10 at 11:52am
• 
  Kolltan Pharmaceuticals added Axel Bolt as Director.
  Posted 1/4/10 at 11:52am
• 
  Kolltan Pharmaceuticals added Arthur Altschul Jr. as Co-Founder, Chairman of the Board.
  Posted 1/4/10 at 11:52am
• 
  Kolltan Pharmaceuticals added Joseph Schlessinger as Co-Founder.
  Posted 10/12/09 at 5:58pm
• 
  Kolltan Pharmaceuticals added Michael Schmertzler as Co-Founder.
  Posted 10/12/09 at 5:58pm
• 
  Kolltan Pharmaceuticals received $25M in Series C funding. (3/8/12)
  Posted 3/11/12 at 7:49pm via masshightech.com
• 
  Kolltan Pharmaceuticals received $10M in Series B funding. (1/20/10)
  Posted 1/4/10 at 11:46am via finsmes.com
• 
  Kolltan Pharmaceuticals received $5M in Series A funding. (10/12/09)
  Posted 10/12/09 at 5:58pm via onbiovc.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/6/10

Sources

1. Kolltan Pharmaceuticals, Inc.: Series A $5M (onbiovc.com) [edit]
2. Kolltan Pharmaceuticals Closes $10M Series B Financing (finsmes.com) [edit]
3. Kolltan Pharma raises $25M in equity offering (masshightech.com) [edit]